RAGE (receptor for advanced glycation end products): a central player in the inflammatory response

被引:236
作者
Chavakis, T [1 ]
Bierhaus, A [1 ]
Nawroth, PP [1 ]
机构
[1] Heidelberg Univ, Dept Internal Med 1, D-69120 Heidelberg, Germany
关键词
innate immunity; glycation; adhesion; leukocyte; integrin;
D O I
10.1016/j.micinf.2004.08.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The present review focuses on the role of RAGE, the "receptor for advanced glycation end products", in the inflammatory response. RAGE is a multiligand receptor that propagates cellular dysfunction in several inflammatory disorders, in tumors and in diabetes. RAGE is expressed at low levels in normal tissues, but becomes upregulated at sites where its ligands accumulate. RAGE may play a dual role in the inflammatory response: (i) interaction of RAGE on leukocytes or endothelial cells (ECs) with its ligands results in cellular activation involving the transcription factor NF-kappaB; (ii) on the other hand, RAGE on ECs may function as an adhesive receptor that directly interacts with leukocyte B2-integrins, thereby directly being involved in inflammatory cell recruitment. These different aspects are discussed in the present review. (C) 2004 Elsevier SAS. All rights reserved.
引用
收藏
页码:1219 / 1225
页数:7
相关论文
共 51 条
[1]  
ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662
[2]   The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins:: a mechanism for producing advances glycation end products at sites of inflammation [J].
Anderson, MM ;
Requena, JR ;
Crowley, JR ;
Thorpe, SR ;
Heinecke, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :103-113
[3]   High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes [J].
Andersson, U ;
Wang, HC ;
Palmblad, K ;
Aveberger, AC ;
Bloom, O ;
Erlandsson-Harris, H ;
Janson, A ;
Kokkola, R ;
Zhang, MH ;
Yang, H ;
Tracey, KJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :565-570
[4]   Chromatin and cell death [J].
Bianchi, ME ;
Manfredi, A .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2004, 1677 (1-3) :181-186
[5]   Diabetes-associated sustained activation of the transcription factor nuclear factor-κB [J].
Bierhaus, A ;
Schiekofer, S ;
Schwaninger, M ;
Andrassy, M ;
Humpert, PM ;
Chen, J ;
Hong, M ;
Luther, T ;
Henle, T ;
Klöting, I ;
Morcos, M ;
Hofmann, M ;
Tritschler, H ;
Weigle, B ;
Kasper, M ;
Smith, M ;
Perry, G ;
Schmidt, AM ;
Stern, DM ;
Häring, HU ;
Schleicher, E ;
Nawroth, PP .
DIABETES, 2001, 50 (12) :2792-2808
[6]   Advanced glycation end product-induced activation of NF-kappa B is suppressed by alpha-lipoic acid in cultured endothelial cells [J].
Bierhaus, A ;
Chevion, S ;
Chevion, M ;
Hofmann, M ;
Quehenberger, P ;
Illmer, T ;
Luther, T ;
Berentshtein, E ;
Tritschler, H ;
Muller, M ;
Wahl, P ;
Ziegler, R ;
Nawroth, PP .
DIABETES, 1997, 46 (09) :1481-1490
[7]   ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGING [J].
BROWNLEE, M .
ANNUAL REVIEW OF MEDICINE, 1995, 46 :223-234
[8]   RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice [J].
Bucciarelli, LG ;
Wendt, T ;
Qu, W ;
Lu, Y ;
Lalla, E ;
Rong, LL ;
Goova, MT ;
Moser, B ;
Kislinger, T ;
Lee, DC ;
Kashyap, Y ;
Stern, DM ;
Schmidt, AM .
CIRCULATION, 2002, 106 (22) :2827-2835
[9]   The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment [J].
Chavakis, T ;
Bierhaus, A ;
Al-Fakhri, N ;
Schneider, D ;
Witte, S ;
Linn, T ;
Nagashima, M ;
Morser, J ;
Arnold, B ;
Preissner, KT ;
Nawroth, PP .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10) :1507-1515
[10]   The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques - Role of glycemic control [J].
Cipollone, F ;
Iezzi, A ;
Fazia, M ;
Zucchelli, M ;
Pini, B ;
Cuccurullo, C ;
De Cesare, D ;
De Blasis, G ;
Muraro, R ;
Bei, R ;
Chiarelli, F ;
Schmidt, AM ;
Cuccurullo, F ;
Mezzetti, A .
CIRCULATION, 2003, 108 (09) :1070-1077